 ROCKAWAY, N.J., Feb. 02, 2021 GLOBE NEWSWIRE -- electroCore, Inc. Nasdaq: ECOR, a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation nVNS for the acute treatment of stroke. TR-VENUS is a double blind, randomized, sham-controlled, multi-center clinical trial, conducted at nine major medical centers across Turkey, supported by the Turkish Neurological Society and partially funded through an unrestricted research grant from electroCore. 